These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38044448)

  • 1. Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes.
    Liu J; Chang X; Ding X; He X; Wang J; Wang G
    Diabetol Metab Syndr; 2023 Dec; 15(1):251. PubMed ID: 38044448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
    Mulder S; Hammarstedt A; Nagaraj SB; Nair V; Ju W; Hedberg J; Greasley PJ; Eriksson JW; Oscarsson J; Heerspink HJL
    Diabetes Obes Metab; 2020 Jul; 22(7):1157-1166. PubMed ID: 32115853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
    Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
    Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin.
    Zhao YX; Borjigin S; Yan ZL
    World J Diabetes; 2022 Mar; 13(3):224-239. PubMed ID: 35432754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
    Mulder S; Heerspink HJL; Darshi M; Kim JJ; Laverman GD; Sharma K; Pena MJ
    Diabetes Obes Metab; 2019 Nov; 21(11):2422-2428. PubMed ID: 31264758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis
    Sun X; Cao Z; Ma Y; Shao Y; Zhang J; Yuan G; Guo X
    Food Funct; 2021 Feb; 12(3):1207-1218. PubMed ID: 33432947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
    Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A
    Cardiovasc Diabetol; 2017 Apr; 16(1):42. PubMed ID: 28376855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DAPA-DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity-A longitudinal cohort study.
    Hanson P; Randeva H; Cuthbertson DJ; O'Hare PJ; Parsons N; Chatha K; Reidy G; Weickert MO; Barber TM
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e381. PubMed ID: 36266774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study.
    Phrommintikul A; Wongcharoen W; Kumfu S; Jaiwongkam T; Gunaparn S; Chattipakorn S; Chattipakorn N
    Br J Clin Pharmacol; 2019 Jun; 85(6):1337-1347. PubMed ID: 30767253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes.
    Feng B; Yu P; Yu H; Qian B; Li Y; Sun K; Shi B; Zhang N; Xu G
    Diabetol Metab Syndr; 2023 Jun; 15(1):141. PubMed ID: 37386620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice.
    Herat LY; Ward NC; Magno AL; Rakoczy EP; Kiuchi MG; Schlaich MP; Matthews VB
    World J Gastroenterol; 2020 Jun; 26(23):3225-3235. PubMed ID: 32684737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety].
    Xu Y; Wu P; Wen W; Chen H
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Nov; 39(11):1305-1311. PubMed ID: 31852646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
    Bletsa E; Filippas-Dekouan S; Kostara C; Dafopoulos P; Dimou A; Pappa E; Chasapi S; Spyroulias G; Koutsovasilis A; Bairaktari E; Ferrannini E; Tsimihodimos V
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1269-1283. PubMed ID: 33592103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.